More ...Close
During a visit to Praimera Biotech AG at the Rock Capital Group's SKYGATE biotech hub in Hallbergmoos, Minister of State Dr Florian Herrmann, MdL, praised the commitment of companies, investors and the community to a strong life sciences location in Bavaria.
The Head of the Bavarian State Chancellery and Minister of State for Federal Affairs and Media, Dr Florian Herrmann, MdL, visited the new research and development facilities of Praimera Biotech AG ("Praimera") at SKYGATE in Hallbergmoos near Munich. The newly founded company recently became part of the growing life science and biotech cluster in the Munich Airport Business Park (MABP) in Hallbergmoos.
Rapid availability is the key to success
"The ready-to-use lab offices at SKYGATE are a prime example of how we are promoting Bavaria as a centre of science. Innovative companies can find immediately usable high-tech laboratory space here - a decisive locational advantage in international competition," emphasised Minister of State Dr Florian Herrmann during his visit. "We need more companies like Praimera Biotech AG, which use their research and development activities to fight serious diseases. In Hallbergmoos, important specialists for our economy and health find ideal conditions for their work. The combination of first-class infrastructure and proximity to Munich Airport makes the Hallbergmoos biotech cluster an important building block for the future of Bavaria as a biotech centre."
Focus on innovation and growth
Praimera is working on a technology platform for the development of the next generation of therapeutic antibodies. The company is utilising the enormous potential of AI-supported drug design and combining machine learning and computer simulation approaches with state-of-the-art laboratory technology. The aim of the platform development is to build a library of new antibody molecules with customised therapeutic properties that will take targeted immunotherapy to a new level. "We are harnessing the immense potential of natural antibodies to develop the next generation of biotherapeutics with fundamentally new therapeutic properties and thus create more effective treatment options for serious chronic and life-threatening diseases, especially in oncology," comments Dr Maximilian Biebl, CEO and CSO of Praimera. Dr Nicolas Combé, member of the Executive Board and CEO/CFO of the company, emphasises the importance of the infrastructure for the company's growth: "Our research and development in the field of innovative antibody therapies requires state-of-the-art laboratory equipment and flexible space. We have found both in SKYGATE - plus an inspiring environment for our employees. The combination of the New Work concept and high-end laboratories enables us to efficiently pursue our ambitious development goals."
Successful cluster development
The Rock Capital Group has already recorded considerable letting successes in SKYGATE in 2024: in addition to Praimera Biotech AG (600 square metres), Samsung SDI Europe (1,500 square metres), Sungrow (600 square metres) and Plectonic Biotech (1,350 square metres) have also recently moved into the building complex. "With the letting of a total of 4,050 square metres of lab offices this year alone, our concept of immediately available S1 and S2 lab space is proving to be exactly right. We are thus closing an important gap in the Munich market and helping companies to start their research activities without delay," explains Andreas Wißmeier, Managing Director of the Rock Capital Group. The Rock Capital Group has now let a total of around 20,000 square metres of labs and lab offices in SKYGATE to well-known tenants from the biotech, healthcare and life sciences sectors. This means that the steadily growing cluster in the MABP near the airport has now established itself as the second-largest cluster in the region alongside the well-known and long-established locations in the south of Munich. And the positive development has not yet come to an end, as there is still more space available for interested tenants to rent.